TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05300542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Placebo Cream
Description: Application of test products before and after irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Placebo Cream
Description: Application of test products before and after irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Cream with 0.5% Active
Description: Application of test products before and after irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Cream with 0.5% Active
Description: Application of test products before and after irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Cream with 1% Active
Description: Application of test products before and after irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Cream with 1% Active
Description: Application of test products before and after irradiation
Study: NCT02579187

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saliva
Description: approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
Study: NCT06186635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional yoga
Description: This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Assisted Yoga
Description: This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
Study: NCT02579187

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: periapical xray
Description: periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: periapical xray
Description: periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: periapical xray
Description: periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
Study: NCT04972916

Intervention type: OTHER
Group type: OTHER
Intervention: Patient navigation-based tobacco harm reduction intervention
Description: At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
Study: NCT02579187

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: periapical xray
Description: periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVS impression
Description: PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVS impression
Description: PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVS impression
Description: PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PVS impression
Description: PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
Study: NCT05520749

Intervention type: DRUG
Intervention: Luspatercept
Description: Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
Study: NCT06211530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpO2 Sensor Testing
Description: Participants participating in this study will be connected to eight (8) Portrait Mobile P-SA01PL/P-SP01PL prototype sensors provided by GEHC and two reference monitors, Nellcor N-600X V 1.6.0.0 and a forehead sensor, used as standard operating procedures at the site. Data will be collected using the Portrait Hub patient monitor. The participants are exposed to a desaturation protocol that sequentially decreases the SpO2 in a stepwise fashion. The goal is to achieve six stable oxygenation plateaus between 100 and 70% SpO2, while recording simultaneous SpO2 readings from the prototype and reference devices. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
Study: NCT05387252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry juice
Description: Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
Study: NCT05225051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy
Study: NCT04745286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline group
Description: Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents.
Study: NCT03097796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042
Description: PUL-042 Inhalation Solution
Study: NCT06264609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
Study: NCT05539326

Intervention type: OTHER
Intervention: Performance Clinical Outcome Test
Description: Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
Study: NCT06653842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTORIN 3.9% rapamycin anhydrous gel
Description: QTORIN 3.9% Rapamycin Anhydrous Gel
Study: NCT05659849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques
Description: Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
Study: NCT06024291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-week HIIT programme
Description: See arm description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity recommendation
Description: See arm description
Study: NCT05212792

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Any licensing COVID-19 vaccine platform

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Any licensing COVID-19 vaccine platform
Study: NCT05762432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound Dressing
Description: RTD Wound Dressing that is being investigated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHS Standard Dressing
Description: This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
Study: NCT06590038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Psychotherapy Intervention
Description: This is a single session intervention which incorporates elements from second- and third wave psychotherapies (Acceptance and Commitment Therapy and Behavioral Activation), as well as basic psychoeducation. Session will take approximately three hours in total, with the option for breaks between blocks of session.
Study: NCT06681272

Intervention type: OTHER
Intervention: Questionnaire
Description: sleep quality assessment using the PROMIS (Patient-Reported Outcomes Measurement Information System) item Bank score

Intervention type: OTHER
Intervention: Questionnaire
Description: assessment of emotional state using the Neuropathic Pain Symptom Inventory score (NPSI)

Intervention type: OTHER
Intervention: Questionnaire
Description: To assess whether pain measured by a Numercial rating scale (NRS) predicts chronic postoperative pain.
Study: NCT06248151

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise session
Description: Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise session
Description: Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control session
Description: Remain seated for 60 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control session
Description: Remain seated for 60 min
Study: NCT06712017

Intervention type: DEVICE
Intervention: Yttrium-90 (Y-90) resin microspheres
Description: selective internal radiation therapy
Study: NCT06717022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHT102 allogeneic CAR T cells
Description: CHT102 allogeneic CAR T cells
Study: NCT06718127

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples collection
Description: blood samples collected at D0 ,W1, W5, M3 and M6
Study: NCT06195826

Intervention type: PROCEDURE
Intervention: Gravity infusion
Description: hysteroscopic myomectomy with the gravity infusion method

Intervention type: PROCEDURE
Intervention: Pump infusion
Description: hysteroscopic myomectomy with the pump infusion method
Study: NCT06044194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine and liposomal vitamin C
Description: Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
Study: NCT05876728

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
Study: NCT06128694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRICAN
Description: Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.
Study: NCT05020249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
Study: NCT06718504

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Glasses
Description: Virtual reality is a method that can be used to distract and prepare patients for medical procedures. Virtual reality is a computer-generated environment where three-dimensional interaction is possible. It is an advanced technology that allows an individual to move into a virtual environment and focus their attention on other thoughts, allowing them to pay less attention to pain and anxiety. In this study, the virtual reality glasses were put on for the intervention group five minutes before the procedure began and were kept on until the procedure was completed. The virtual reality glasses showed the patient-selected images of a relaxing nature setting or images without any violent content.
Study: NCT06717906

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endoscopic Ultrasound
Description: If sigmoidoscopy is warranted as per clinical indication, the consenting patients shall undergo endoscopic ultrasound (EUS) using a radial echo-endoscope during the same sitting of sigmoidoscopy without incurring any additional cost to the patient. Total rectal wall thickness in anterior and posterior wall shall be measured in upper, middle and lower rectum with assessment of vascularity (Modified Limberg scale). The maximal wall thickness including maximum mucosal and submucosal thickness shall be noted and compared to total wall thickness measured by transabdominal ultrasound (TAS) and Transperineal ultrasound (TPUS). On sigmoidoscopy, rectal inflammation shall be measured by ulcerative colitis endoscopic index of severity (UCEIS) in rectum. Biopsy seal be taken as standard protocol to document histologic inflammation (measured by Nancy histologic index) which is known to predict future risk of relapse.
Study: NCT06719063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Virtual Reality
Description: The VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion occurs through the simultaneous stimulation of four of the five senses.~Session duration: 45 minutes, with 15 minutes dedicated to the protocol administration. The remaining 30 minutes will be used to welcome the patient, explain the content of the session, and review the session's outcome, particularly to assess tolerance (Simulator Sickness Questionnaire (SSQ) completed at the start of each week after the first VirtySens® session). The sessions will take place in the morning to prevent the session from being disrupted by fatigue related to the rehabilitation day.
Study: NCT06715865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thymus Transplantation
Description: Thymus Transplantation
Study: NCT06718205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W
Study: NCT05020249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
Study: NCT06718205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle
Study: NCT06716398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product
Description: Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator product
Description: Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
Study: NCT06716216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 5 mg BGM0504 Administered SC
Description: Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug:10 mg BGM0504 Administered SC
Description: Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Semaglutide Administered SC
Description: Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week
Study: NCT06717542

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histochemical and immunohistochemical analysis
Description: 2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histochemical and immunohistochemical analysis
Description: 2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RT-PCR
Description: Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).
Study: NCT03786237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib Oral Capsules / Rigosertib Intravenous
Description: Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter.